US · CASI
CASI Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Beijing, MD 20850
- Website
- casipharmaceuticals.com
Price · as of 2024-12-31
—
Market cap 3.21M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $12.09 | — |
| Intrinsic Value(DCF) | $0.88 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $17.87 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $49.40 | $621.12 | $3.35 | $0.00 | $173.73 |
| 2011 | $22.70 | $116.10 | $2.39 | $0.00 | $143.97 |
| 2012 | $24.00 | $318.73 | $4.57 | $0.00 | $416.91 |
| 2013 | $18.30 | $41.01 | |||
| 2014 | $14.90 | $0.00 | $0.00 | ||
| 2015 | $8.60 | $59.40 | $0.00 | $0.00 | $0.00 |
| 2016 | $14.40 | $27.59 | |||
| 2017 | $33.10 | ||||
| 2018 | $31.60 | ||||
| 2019 | $18.00 | $2.61 | $0.00 | ||
| 2020 | $24.80 | $44.74 | $2,514.22 | $0.00 | $0.00 |
| 2021 | $9.10 | $30.54 | $46,401.65 | $0.00 | $0.00 |
| 2022 | $1.85 | $24.93 | $55,968.58 | $0.00 | $0.00 |
| 2023 | $4.87 | $23.05 | $13.10 | $0.00 | $24.88 |
| 2024 | $2.20 | $12.09 | $0.00 | $0.00 | $17.87 |
AI valuation
Our deep-learning model estimates CASI Pharmaceuticals, Inc.'s (CASI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $12.09
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.88
— upside
Graham-Dodd
—
— upside
Graham Formula
$17.87
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CASI | CASI Pharmaceuticals, Inc… | $0.21 | 3.21M | +5,727% | +324% | — | +8,512% | -0.86 | 18.23 | 1.18 | -1.14 | -3.22 | 20.92 | 39.06% | -138.84% | -137.57% | -301.80% | -351.62% | -60.89% | 11.96 | -45.49 | 1.09 | 0.86 | -0.25 | 2673.00% | -1577.00% | 3267.00% | -87.31% | -0.80 | -261.48% | 2.13% | -1.80% | 2.13% | -1.00 | -1.35 | 1.39 | -19.70 |
| ALLR | Allarity Therapeutics, In… | $0.97 | 15.6M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CLSD | Clearside Biomedical, Inc… | $0.41 | 2.15M | +4,171% | +1,944,915% | — | +116,036% | -1.99 | -1.76 | 41.15 | -4.15 | — | -1.76 | 91.05% | -1735.70% | -2064.42% | 125.45% | 701.36% | -116.16% | -1.35 | -2.95 | 4.44 | 4.28 | 0.79 | -1132.00% | -7977.00% | 2894.00% | -37.50% | -5.15 | 623.48% | 0.00% | 0.00% | 48.77% | -3.49 | -3.93 | 60.65 | -22.09 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| LSTA | Lisata Therapeutics, Inc. | $4.10 | 36.16M | — | -69% | — | — | -0.98 | 0.66 | 19.66 | 0.52 | — | 0.67 | 100.00% | -2240.90% | -1998.50% | -51.43% | 1147.42% | -44.56% | 0.00 | — | 6.16 | 5.73 | 0.72 | -698.00% | — | -337.00% | -98.47% | -3.45 | 1030.67% | 0.00% | 0.00% | 0.00% | 0.51 | 0.59 | -11.45 | -20.94 |
| NCNA | NuCana plc | $2.16 | 13.12M | — | — | — | — | -41.51 | 132.44 | — | -34.78 | — | 210.00 | 0.00% | — | — | -182.30% | 1515.50% | -89.22% | 0.03 | — | 1.42 | 1.31 | 0.29 | -3771.00% | — | -2789.00% | -2.46% | -2.21 | 1524.22% | 0.00% | 0.00% | 0.00% | -34.28 | -40.29 | — | 27.59 |
| PALI | Palisade Bio, Inc. | $1.77 | 263.74M | +38% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
- CEO
- David A. Cory
- Employees
- 233
- Beta
- 0.89
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.88 ÷ —) − 1 = — (DCF, example).